DDInter1828 DDInter1055
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Tolbutamide {u} may lead to a major life threatening interaction when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Tolbutamide {u} may lead to a major life threatening interaction when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Tolbutamide {u} may lead to a major life threatening interaction when taken with {v} Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Tolbutamide {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Tolbutamide {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Levofloxacin
Tolbutamide {u} may lead to a major life threatening interaction when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Ciprofloxacin
Ciprofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Tolbutamide {u} may lead to a major life threatening interaction when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Tolbutamide {u} may lead to a major life threatening interaction when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Tolbutamide {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Ofloxacin
Ofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Tolbutamide {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Ciprofloxacin
Ciprofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Tolbutamide may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) resembles Levofloxacin (Compound)
Tolbutamide may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Levofloxacin (Compound)
Tolbutamide may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Tolbutamide (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Levofloxacin (Compound)
Tolbutamide (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Levofloxacin (Compound)
Tolbutamide may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) resembles Ciprofloxacin (Compound) and Ciprofloxacin (Compound) resembles Levofloxacin (Compound)
Tolbutamide may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Tolbutamide may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Tolbutamide (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Ofloxacin (Compound) and Ofloxacin (Compound) resembles Levofloxacin (Compound)
Tolbutamide (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Ciprofloxacin (Compound) and Ciprofloxacin (Compound) resembles Levofloxacin (Compound)